Genomic Medicine
Targeted Base Editing in Vivo: Next-Gen Lipid Nanoparticles Clear Phase II Liver Trials
Engineered organ-tropic lipid nanoparticles deliver single-base cytosine editors directly to hepatocytes with 94% knockdown efficiency and undetectable off-target cuts.